Evotec (ETR:EVT) Stock Price Down 6.7% – What’s Next?

Evotec SE (ETR:EVT)’s share price was down 6.7% during trading on Wednesday . The stock traded as low as €5.23 and last traded at €5.30. Approximately 1,386,983 shares were traded during trading, an increase of 2% from the average daily volume of 1,360,000 shares. The stock had previously closed at €5.69.

Evotec Trading Down 6.7%

The company has a debt-to-equity ratio of 60.57, a current ratio of 2.12 and a quick ratio of 2.97. The company has a market capitalization of $984.13 million, a P/E ratio of -5.74, a price-to-earnings-growth ratio of 0.98 and a beta of 1.05. The firm has a fifty day moving average price of €5.98 and a 200-day moving average price of €6.00.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.